Publication: Paclitaxel delivery using carrier made from curcumin derivative: Synergism between carrier and the loaded drug for effective cancer treatment
2
Issued Date
2012-01-01
Resource Type
ISSN
15206017
00223549
00223549
Other identifier(s)
2-s2.0-84865350113
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Pharmaceutical Sciences. Vol.101, No.10 (2012), 3779-3786
Suggested Citation
Kittima Amornwachirabodee, Khajeelak Chiablaem, Sumrit Wacharasindhu, Kriengsak Lirdprapamongkol, Jisnuson Svasti, Viwat Vchirawongkwin, Supason P. Wanichwecharungruang Paclitaxel delivery using carrier made from curcumin derivative: Synergism between carrier and the loaded drug for effective cancer treatment. Journal of Pharmaceutical Sciences. Vol.101, No.10 (2012), 3779-3786. doi:10.1002/jps.23263 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/15183
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Paclitaxel delivery using carrier made from curcumin derivative: Synergism between carrier and the loaded drug for effective cancer treatment
Other Contributor(s)
Abstract
To fully make use of the synergism between paclitaxel and curcumin (CUR) in cancer treatment, carrier made from CUR derivative was synthesized and used to deliver paclitaxel into cancer cells. The methoxylpolyethylene oxide-linked palmitate-modified curcumin (mPEO-CUR-PA) was synthesized and the obtained amphiphilic mPEO-CUR-PA molecules were allowed to self-assemble into microspheres. In vitro release of free CUR from mPEO-CUR-PA in the presence of lipase was proofed and the ability of cells to endocytose mPEO-CUR-PA microspheres was verified. Cytotoxic activity of the mPEO-CUR-PA microspheres toward cancer cell lines (S102 and A549) was evaluated and compared with that of the unmodified CUR. Paclitaxel was then loaded into the microspheres and the paclitaxel-loaded mPEO-CUR-PA microspheres showed up to fivefold to 44-fold increased in vitro cytotoxicity (in terms of % cell mortality) in susceptible (HCC-S102 and A549) and paclitaxel-resistant (A549RT-eto) cancer cells, respectively, compared with that of free paclitaxel. © 2012 Wiley Periodicals, Inc.